Results 31 to 40 of about 137,977 (285)
Response to the Remarks of the President of Marquette University, by Emory T. Clark, 1982 [PDF]
Response to the Remarks of the President of Marquette University, by Emory T. Clark, upon the occasion of the formal dedication of Emory T.
Clark, Emory T.
core
Xstainer: A Novel Virtual Staining Tool Powered by Advanced Deep Learning Techniques
Xstainer is a deep learning–based virtual staining framework that converts hematoxylin and eosin‐stained whole slide images into multiple histochemical stains, including Masson's trichrome, Periodic acid‐Schiff, Jones methenamine silver, and Toluidine blue.
Fatma Nur Kinali +15 more
wiley +1 more source
Ram Jagannathan,1 Kanya Rajagopalan,2 Julien Hogan,3,4 Allyson Hart,5,6 Kenneth A Newell,4 Stephen O Pastan,7 Rachel E Patzer4,7,8 1Department of Medicine, Division of Hospital Medicine, Emory University School of Medicine, Atlanta, GA, USA; 2Department ...
Jagannathan R +6 more
doaj
Review of The Bluestocking Archive, Emory Women Writers Resource Project, and Women's Travel Writing 1780-1840.
Megan Peiser
doaj +1 more source
The Fifteenth Annual EMORY BANKRUPTCY DEVELOPMENTS JOURNAL SYMPOSIUM February 22, 2018 | 8:00 a.m. to 1:00 p.m.
Emory Bankruptcy Developments Journal
core +1 more source
ABSTRACT Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA (n = 35) or alloHSCT (n = 31). Baseline characteristics
Saubia Fathima +48 more
wiley +1 more source
McGirt v. Oklahoma: Implications of the 2020 Supreme Court Decision for Native America
On October 12, 2020, four Native American scholars, jurists, and activists engaged in a panel discussion (via Zoom) that examined the historical contexts and implications of the US Supreme Court’s McGirt v.
doaj +1 more source
ABSTRACT Frameshift mutations in exon 12 of nucleophosmin 1 (NPM1mut) are among the most common mutations in acute myeloid leukemia (AML) and have historically been considered favorable‐risk in the absence of FLT3‐ITD. In the European LeukemiaNet (ELN) 2024 risk‐classification for patients treated with hypomethylating agents plus venetoclax (HMA + VEN),
Fieke W. Hoff +44 more
wiley +1 more source

